These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 17268543)

  • 1. Treatment with biologic therapies and the risk of cancer in patients with IBD.
    Biancone L; Calabrese E; Petruzziello C; Pallone F
    Nat Clin Pract Gastroenterol Hepatol; 2007 Feb; 4(2):78-91. PubMed ID: 17268543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
    Reddy JG; Loftus EV
    Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.
    Lichtenstein GR; Diamond RH; Wagner CL; Fasanmade AA; Olson AD; Marano CW; Johanns J; Lang Y; Sandborn WJ
    Aliment Pharmacol Ther; 2009 Aug; 30(3):210-26. PubMed ID: 19392858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.
    Cottone M; Kohn A; Daperno M; Armuzzi A; Guidi L; D'Inca R; Bossa F; Angelucci E; Biancone L; Gionchetti P; Ardizzone S; Papi C; Fries W; Danese S; Riegler G; Cappello M; Castiglione F; Annese V; Orlando A
    Clin Gastroenterol Hepatol; 2011 Jan; 9(1):30-5. PubMed ID: 20951835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
    Caspersen S; Elkjaer M; Riis L; Pedersen N; Mortensen C; Jess T; Sarto P; Hansen TS; Wewer V; Bendtsen F; Moesgaard F; Munkholm P;
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1212-7; quiz 1176. PubMed ID: 18848503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
    Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to improve the safety of biologic therapy in Crohn's disease.
    Ferkolj I
    J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease.
    Orlando A; Mocciaro F; Civitavecchia G; Scimeca D; Cottone M
    Dig Liver Dis; 2008 Jul; 40 Suppl 2():S236-46. PubMed ID: 18598995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab use in children and adolescents with inflammatory bowel disease.
    de Ridder L; Benninga MA; Taminiau JA; Hommes DW; van Deventer SJ
    J Pediatr Gastroenterol Nutr; 2007 Jul; 45(1):3-14. PubMed ID: 17592358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse effects of biologics used for treating IBD.
    Stallmach A; Hagel S; Bruns T
    Best Pract Res Clin Gastroenterol; 2010 Apr; 24(2):167-82. PubMed ID: 20227030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety issues with biological therapies for inflammatory bowel disease.
    Van Assche G; Vermeire S; Rutgeerts P
    Curr Opin Gastroenterol; 2006 Jul; 22(4):370-6. PubMed ID: 16760752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease.
    Bousvaros A
    Expert Rev Clin Immunol; 2010 Jul; 6(4):659-66. PubMed ID: 20594138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refractory Takayasu arteritis successfully treated with infliximab.
    Maffei S; Di Renzo M; Santoro S; Puccetti L; Pasqui AL
    Eur Rev Med Pharmacol Sci; 2009; 13(1):63-5. PubMed ID: 19364087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging biological treatments in inflammatory bowel diseases.
    Van Assche G; Vermeire S; Rutgeerts P
    Dig Dis; 2006; 24(1-2):131-6. PubMed ID: 16699271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
    Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
    Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronic inflammatory bowel disease - new therapies: tumor necrosis factor-antibodies and cytokines].
    Stange EF
    Z Gastroenterol; 2002 Apr; 40 Suppl 1():S90-S1. PubMed ID: 11930299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.
    Fiorino G; Allez M; Malesci A; Danese S
    Aliment Pharmacol Ther; 2009 May; 29(9):921-7. PubMed ID: 19210297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
    Van Assche G; Lewis JD; Lichtenstein GR; Loftus EV; Ouyang Q; Panes J; Siegel CA; Sandborn WJ; Travis SP; Colombel JF
    Am J Gastroenterol; 2011 Sep; 106(9):1594-602; quiz 1593, 1603. PubMed ID: 21844919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing response and loss of response to biological therapies in IBD.
    Yanai H; Hanauer SB
    Am J Gastroenterol; 2011 Apr; 106(4):685-98. PubMed ID: 21427713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.